OMCL — Omnicell Inc. Common Stock ($0.001 par value) stock price and chart

OMCL

$36.49+1.90%

as of close, Oct 20, 2026

☾ AH $36.49 +1.90%

Omnicell Inc. Common Stock ($0.001 par value)Stock · HealthcareRussell 2000 · 0.06% of IWMNasdaq Composite · 0.007% of ONEQRussell 3000 · 0.002% of IWVUS Stock Market · 0.002% of VTI

PeersMRNALLYMDTUNHJNJTMO

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEEEEEEEEEE

20162019202120242026

40.060.080.0100.0120.0140.0160.0180.0010.0M$36.49

2026-10-20

Price$36.49

MA20$38.78

MA50$38.16

Vol1.7M

What would $1,000 invested in OMCL be worth today? →

OMCL returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $36.49
YTD price return: -19.45%
YTD total return: -19.45%
Next earnings: Oct 29, 2026 · Before open
Market cap: 1.7B2016-12 1.2B2026-10 1.7B+34.5% over the window
Enterprise value: 1.4B
Shares outstanding: 45.6M2016-06 36.2M2026-06 45.6M+26.1% over the window
52W low: $29.09
52W high: $55.00
From 52W high: -33.65%
From 52W low: +25.44%
52W range: 29%

Volume

Rel volume: 0.91×
30D volume: 486.5K
30D $ vol: 16.6M

Fundamentals

Sales (ttm): 1.2B2016-06 599.5M2026-06 1.2B+108.0% over the window
Sales/share: $27.332016-06 $16.582026-06 $27.33+64.9% over the window
EPS (ttm): $0.852016-06 $0.392026-06 $0.85+117.4% over the window
FCF (ttm): 142.6M2016-12 36.5M2026-06 142.6M+291.2% over the window
FCF/share: $3.132016-12 $0.992026-06 $3.13+216.9% over the window
Book value/share: $28.322016-06 $11.432026-06 $28.32+147.8% over the window
Net margin: 3.13%2016-06 2.4%2026-06 3.1%+32.8% over the window
ROE: 3.03%2016-06 3.4%2026-06 3.0%-11.7% over the window
ROA: 1.96%2016-06 1.5%2026-06 2.0%+26.2% over the window
Current ratio: 1.642016-06 1.632026-06 1.64+0.8% over the window

Growth (CAGR, ttm) · 10Y

Sales: +8.46%2025-06-30 → 2026-06-301.1B → 1.2B (+8.5% total)+0.31%2023-06-30 → 2026-06-301.2B → 1.2B (+0.9% total)+4.77%2021-06-30 → 2026-06-30987.5M → 1.2B (+26.3% total)+7.60%2016-06-30 → 2026-06-30599.5M → 1.2B (+108.0% total)
Net income: +69.34%2025-06-30 → 2026-06-3023.1M → 39.1M (+69.3% total)n/a-8.14%2021-06-30 → 2026-06-3059.7M → 39.1M (-34.6% total)+10.69%2016-06-30 → 2026-06-3014.2M → 39.1M (+176.1% total)
FCF: +33.50%2025-06-30 → 2026-06-30106.8M → 142.6M (+33.5% total)+0.43%2023-06-30 → 2026-06-30140.8M → 142.6M (+1.3% total)-8.44%2021-06-30 → 2026-06-30221.6M → 142.6M (-35.7% total)+15.67%2015-12-31 → 2026-06-3030.9M → 142.6M (+360.8% total)
Shares: -0.70%2025-06-30 → 2026-06-3045.9M → 45.6M (-0.7% total)+0.30%2023-06-30 → 2026-06-3045.2M → 45.6M (+0.9% total)+0.97%2021-06-30 → 2026-06-3043.5M → 45.6M (+4.9% total)+2.35%2016-06-30 → 2026-06-3036.2M → 45.6M (+26.1% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +72.63%2025-06-30 → 2026-06-30$0.49 → $0.85 (+72.6% total)n/a-8.38%2021-06-30 → 2026-06-30$1.32 → $0.85 (-35.4% total)+8.08%2016-06-30 → 2026-06-30$0.39 → $0.85 (+117.4% total)
Sales/share: +9.22%2025-06-30 → 2026-06-30$25.03 → $27.33 (+9.2% total)+0.01%2023-06-30 → 2026-06-30$27.32 → $27.33 (+0.0% total)+3.77%2021-06-30 → 2026-06-30$22.71 → $27.33 (+20.3% total)+5.13%2016-06-30 → 2026-06-30$16.58 → $27.33 (+64.9% total)
FCF/share: +34.43%2025-06-30 → 2026-06-30$2.33 → $3.13 (+34.4% total)+0.13%2023-06-30 → 2026-06-30$3.11 → $3.13 (+0.4% total)-9.32%2021-06-30 → 2026-06-30$5.10 → $3.13 (-38.7% total)+13.04%2015-12-31 → 2026-06-30$0.86 → $3.13 (+262.0% total)
Book value/share: +2.93%2025-06-30 → 2026-06-30$27.51 → $28.32 (+2.9% total)+3.23%2023-06-30 → 2026-06-30$25.74 → $28.32 (+10.0% total)+3.18%2021-06-30 → 2026-06-30$24.21 → $28.32 (+17.0% total)+9.50%2016-06-30 → 2026-06-30$11.43 → $28.32 (+147.8% total)
Price: +20.84%2025-10-20 → 2026-10-20$30.20 → $36.49 (+20.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-2.71%2023-10-20 → 2026-10-20$39.63 → $36.49 (-7.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-26.05%2021-10-20 → 2026-10-20$165.01 → $36.49 (-77.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+0.23%2016-10-19 → 2026-10-20$35.65 → $36.49 (+2.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +20.84%2025-10-20 → 2026-10-20$30.20 → $36.49 (+20.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-2.71%2023-10-20 → 2026-10-20$39.63 → $36.49 (-7.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-26.05%2021-10-20 → 2026-10-20$165.01 → $36.49 (-77.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+0.23%2016-10-19 → 2026-10-20$35.65 → $36.49 (+2.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 42.9×2016-12 152.822026-10 42.59-72.1% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 28.7×2016-12 66.442026-10 28.72-56.8% over the window
Fwd P/E: 17.4×
P/S (ttm)Market cap ÷ TTM revenue.: 1.3×2016-12 1.902026-10 1.34-29.8% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 1.3×2016-12 2.902026-10 1.29-55.5% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 11.7×2016-12 40.012026-10 11.67-70.8% over the window
EV/EBITDA (fy): 10.4×
EV/Sales (ttm): 1.1×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 8.57%2016-12 2.9%2026-06 7.5%+155.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 45.6M ÷ 45.9M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 0.70%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (0.70%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.4B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 0.70%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($61.9M) ÷ today's market cap ($1.7B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 3.72%2016-09 0.0%2026-06 3.3%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $61.9M + TTM dividends $0) ÷ today's market cap ($1.7B). Same caveat as the cash buyback yield.: 3.72%2016-09 0.0%2026-06 3.3%

Vs own 10Y history

P/E: 7th
P/OI: 2nd
P/S: 14th
P/B: 15th
P/FCF: 13th

Bar = where today’s multiple sits in OMCL’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-20#

+1.90%

+0.11%

+13.22%

-19.31%

YTD

-19.45%

+20.83%

-77.89%

Financial statements

Open full OMCL financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+11.34%	+3.49%
JNJ	Johnson & Johnson	-3.94%	+2.19%
ABBV	AbbVie Inc.	+9.52%	+2.26%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+11.24%	+3.04%
MRK	Merck & Co. Inc.	+0.97%	+3.25%
NVS	Novartis AG	+9.45%	+2.29%
TMO	Thermo Fisher Scientific Inc.	+5.51%	+1.18%
AMGN	Amgen Inc.	+13.82%	+3.29%

OMCL — Omnicell Inc. Common Stock ($0.001 par value) price, chart and key statistics